MHRA authorises HIPRA Human Health's COVID-19 vaccine for use in UK

02 Aug 2023
www.pmlive.com
VaccineDrug ApprovalmRNAClinical Study
MHRA authorises HIPRA Human Health's COVID-19 vaccine for use in UK
Preview
Source: PMLiVE
The Medicines and Healthcare products Regulatory Agency (MRHA) has authorised HIPRA Human Health’s COVID-19 vaccineCOVID-19 vaccine, Bimervax, after it met the regulator’s required safety, quality and effectiveness standards.
HIPRA, a biotech company that provides vaccines and diagnostic services, developed Bimervax, which combines part of the SARS-CoV-2 virus spike protein with an additional ingredient designed to trigger a stronger immune response, known as an adjuvant.
The new COVID-19 vaccine will be given as a booster injection to eligible individuals aged 16 years and over.
The regulator’s decision was based on data from a study of 765 adults who received primary vaccination with two doses of the Comirnaty COVID-19 vaccineCOVID-19 vaccine and then a booster dose of either Bimervax or Comirnaty.
Bimervax showed a strong immune response, and common side effects were mild and self-resolved within a few days of vaccination.
The MRHA’s authorisation comes less than a month after HIPRA said it would be initiating a clinical trial to evaluate the safety and immune response of Bimervax when co-administered with the seasonal influenza vaccine.
The study, which will involve 300 adults aged 65 or older who were first vaccinated against COVID-19 with an mRNA vaccine, has been authorised by the Spanish Agency for Medicines and Health Products and will last two months.
Bimervax is now the ninth COVID-19 vaccine to be authorised by the MRHA.
The MRHA authorised SK Chemicals’s SKYCovion earlier this year for use as a primary vaccination in those aged 18 and over, making it the eighth COVID-19 vaccineCOVID-19 vaccine to be approved by the regulator.
Its decision was based on data from two clinical trials of approximately 3,100 individuals between the ages of 18 and 84. SKYCovion demonstrated a strong immune response, with only mild common side effects that resolved on their own soon after vaccination.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.